Compare RXRX & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXRX | LMAT |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2021 | 2006 |
| Metric | RXRX | LMAT |
|---|---|---|
| Price | $3.50 | $112.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $7.50 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 10.4M | 162.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.89% |
| EPS Growth | 14.79 | ★ 30.57 |
| EPS | N/A | ★ 2.52 |
| Revenue | $74,681,000.00 | ★ $249,602,000.00 |
| Revenue This Year | $12.11 | $14.21 |
| Revenue Next Year | $82.52 | $8.88 |
| P/E Ratio | ★ N/A | $44.70 |
| Revenue Growth | ★ 26.92 | 13.53 |
| 52 Week Low | $2.80 | $78.01 |
| 52 Week High | $7.18 | $118.01 |
| Indicator | RXRX | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 54.93 |
| Support Level | $2.89 | $80.90 |
| Resistance Level | $3.99 | $113.40 |
| Average True Range (ATR) | 0.17 | 2.74 |
| MACD | 0.04 | -0.48 |
| Stochastic Oscillator | 52.41 | 49.62 |
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.